Ann: PD1-Vaxx Presentation at ESMO Congress 2021 Annual Meeting, page-37

From my understanding what is really interesting is that the IMU treatments are being tested on patients that fall within a cohort of individuals who are particularly unwell. I would value a view on how the Treatments are anticipated to work on patients who are in early stage of illness. I am approaching this from a non medical understanding but will the human body react differently having regard to the degree of illness. In this regard is there an immediate reaction to treatment where the patients are severely unwell compared to early stages of the illness or just diagnosed. If just diagnosed there may be limits on being able to subscribe for trials. Apologies if my line of enquiry is misdirected but it’s something that I have been pondering. Look forward to observations from the group.